E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Histologically confirmed diagnosis of hepatocellular carcinoma. Patients with the fibrolamellar histology or a mixed histology are not eligible. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Level | VTc |
E.1.2 | Classification code | 10019697 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the antitumor activity of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks repeated every 6 weeks in patients with unresectable hepatocellular carcinoma. |
|
E.2.2 | Secondary objectives of the trial |
- To assess measures of clinical benefit and duration of tumor control - To evaluate the safety and tolerability of SU011248 - To evaluate SU011248 and SU012662 trough concentrations (Ctrough) and to correlate these plasma concentrations with activity and safety parameters - To explore the correlations of cancer biomarkers with cancer- and treatment- related outcomes.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed diagnosis of hepatocellular carcinoma. Patients with the fibrolamellar histology or a mixed histology are not eligible. 2. Patients must present with disease not amenable to curative surgery (i.e. either hepatectomy, or liver transplant). 3. Patients previously undergoing local treatment, such as surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneaous ethanol injection, or cryoablation are eligible if they have subsequently progressed or recurred. A minimum delay of 4 weeks is required between local therapy and progression. 4. Resolution of all acute toxic effects of any prior local treatment to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 3.0) grade less than/ equal to 1. 5. Measurable disease according to RECIST. 6. No cirrhosis or cirrhotic status up to Child-Pugh class B. 7. 18 years of age or older. 8. ECOG performance status 0 or 1. 9. Required baseline laboratory data within the following parameters: - Neutrophils ≥1,500/mL - Platelets ≥60,000/mL - Hemoglobin ≥8.5 g/dL - Serum albumin≥2.8 g/dL - Serum bilirubin less than/equal to 3 mg/dL - Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) less than /equal to 5 x ULN - INR less thna /equal to 1.7 or Prothrombin time (PT) less than/equal to 6 sec over ULN - Serum creatinine < 1.5 x ULN. 10. Life-expectancy of ≥ 3 months. 11. Signed and dated an informed consent indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. 12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
|
|
E.4 | Principal exclusion criteria |
1. Prior treatment with any systemic treatment for HCC. 2. Prior treatment on a SU011248 clinical trial. 3. Prior local therapy (such as surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) of target lesions at any prior time, unless progressed or recurred as per RECIST or WHO. 4. Prior history of liver transplant. 5. Presence of clinically relevant ascites (i.e. requiring paracentesis). 6. NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment. 7. Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months. 8. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. 9. Any of the following within the 12 months prior to study drug administration: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism. 10. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any grade, or prolongation of the QTc interval to > 450 msec for males or > 470 msec for females. 11. Hypertension that cannot be controlled by medications (blood pressure >150/90 mmHg despite optimal medical therapy). 12. Treatment with anticonvulsant agents and treatment with therapeutic doses of warfarin currently or within 2 weeks prior to first day of SU011248 administration. Low dose warfarin for DVT prophylaxis is permitted (up to 2 mg/day). Low molecular weight heparin is allowed. 13. Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea. 14. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. 15. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to enrollment. 16. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study. 17. Receipt of any investigational agent prior to study entry. 18. Current treatment on another therapeutic clinical trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective response rate (ORR) as determined according to RECIST |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
All patients will receive repeated cycles of SU011248 until disease progression, occurrence of unacceptable toxicity, or withdrawal of patient consent. After discontinuation of treatment and the mandated 28-day follow up, patients will be followed only in order to collect information on further antineoplastic therapy and survival. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |